The Virtus Diversified Income & Convertible Fund (ACV) has delivered strong total returns recently, helped by a narrowing discount to its net asset value and solid performance in the technology sector. The fund currently trades at a small discount of -1.31% and offers a yield of 7.94%. However, its heavy exposure to tech stocks and convertible securities raises concerns amid high equity valuations. While the fund's stable distributions are attractive, the payout relies more on capital gains than net investment income, making its sustainability sensitive to market fluctuations. The analyst remains neutral on ACV, preferring to wait for a wider discount or market correction before investing due to current valuations and sector concentration risks.
Zentalis Pharmaceuticals awarded 136,000 non-qualified stock options to four newly hired employees as an inducement to join the company, under Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $1.85, matching the stock's closing p...
Dianthus Therapeutics, a clinical-stage biotech company, granted stock options to three new non-executive employees as inducements for joining the company. The options cover 26,000 shares at an exercise price of $82.25, vesting over four years. This ...
The Federal Home Loan Bank of Atlanta announced the election of three new member directors and the re-election of one independent director to its board for 2026. Suzanne DeFerie was named Chair and Kathy McKinney Vice Chair for 2027, ensuring experie...
On November 2, USDC Treasury minted 1 billion USD Coin (USDC) tokens on the Solana blockchain within a 10-minute window, transferring them to a Circle-controlled account in four transactions of 250 million USDC each. This issuance is double the 500 m...
AAR Corp has priced $955 million of 7.125% senior notes due 2031 and $960 million of 7.375% senior notes due 2034, totaling $1.915 billion. The proceeds, along with equity issuance and credit facility borrowings, will fund its acquisition of a contro...
